Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039130 · ClinicalTrials.gov registry record · Phase 2
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
A Phase 2 study of Lymphoma and Leukemia, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT00039130: Completed Phase 2 study of Lymphoma and Leukemia, sponsored by Alliance for Clinical Trials in Oncology.
NCT00039130 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 105 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039130, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the numbers of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with rituximab and filgrastim may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with chemotherapy and filgrastim in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.
Primary Outcome
Response is assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Complete response requires disappearance of all evidence of disease.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- DRUG dexamethasone
- BIOLOGICAL filgrastim
- DRUG cytarabine
Study Locations (20)
New York
- Roswell Park Cancer Institute - Buffalo
- Monter Cancer Center of the North Shore-LIJ Health System - Lake Success
- CCOP - North Shore University Hospital - Manhasset
- Don Monti Comprehensive Cancer Center at North Shore University Hospital - Manhasset
- Long Island Jewish Medical Center - New Hyde Park
Delaware
- Tunnell Cancer Center at Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
Illinois
- University of Illinois Cancer Center - Chicago
- University of Chicago Cancer Research Center - Chicago
Iowa
- Hematology Oncology Associates of the Quad Cities - Bettendorf
- Holden Comprehensive Cancer Center at University of Iowa - Iowa City
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
- Union Hospital Cancer Program at Union Hospital - Elkton
California
- Naval Medical Center - San Diego - San Diego
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2002-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
What the finished NCT00039130 record still lists
NCT00039130 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00039130 names 20 study sites across 12 states, led by New York, Delaware, Illinois.
Frequently Asked Questions
What is clinical trial NCT00039130 about?
NCT00039130 is a clinical study titled "Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia". RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating fa...
What is the current status of trial NCT00039130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2002-05. Estimated completion is 2014-10.
What conditions does trial NCT00039130 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia.
What interventions are being tested in trial NCT00039130?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), dexamethasone (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00039130?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00039130 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00039130's enrollment target sits among peer trials
105 76th of 299 higher than 224 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia